We'll have to agree to disagree there - if you want to track the trajectory of the underlying business, especially when one-off non-cash expenses are being booked, EBIT is the only way to go.
"Competitor snapping at the heels"?? BEACON is a P2 study which only initiated this month so that compound is still 3-4 years away from approval, if it makes it at all.
Ann: Appendix 4E and Annual Report 2022, page-8
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.48 |
Change
0.000(0.00%) |
Mkt cap ! $724.8M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 62 | $15.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.76 | 48 | 1 |
View Market Depth
| Last trade - 09.55am 03/10/2024 (20 minute delay) ? |
| CUV (ASX) Chart |
Day chart unavailable